TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
The Chemokine Fragment CXCL9(74-103) Diminishes Neutrophil Recruitment and Joint Inflammation in Antigen-Induced Arthritis
Katrina Wilhelm, ND is a board-certified naturopathic physician with a passion for functional medicine
It mimics ghrelin and binds to the ghrelin receptor (GHSR) in the brain, selectively stimulating GH release from the pituitary gland, which increases plasma GH levels